Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Japanese drugmaker Takeda sounds out possible lenders as it edges closer to US$50bn bid for Shire

According to two Reuters sources with direct knowledge of the matter, Takeda has spoken with several banks about borrowing tens of billions of dollars to fund the possible acquisition of Shire
microscope in laboratory
If the deal goes through, it will likely be the largest overseas acquisition ever by a Japanese company

Takeda Pharmaceutical has moved a step closer to lodging a US$50bn bid for Shire PLC (LON:SHP) after reports emerged that Japan’s largest drugmaker has sounded out its major creditors for loans to help fund the deal.

Buying Shire would be transformational for Takeda, which believes a deal would strengthen its core therapeutic areas of oncology, gastroenterology and neuroscience, while Shire’s rare disease franchise would also boost its position in specialised medicines.

READ: Takeda considers takeover offer for Shire

But it won’t be easy, and any deal would be a huge financial stretch, given that Shire is worth around US$10bn more than the Japanese group.

Shire first told investors about Takeda’s interest at the end of March and expectations that a bid will be lodged before the April 25 deadline have mounted since Takeda’s boss Christophe Weber held a meeting with analysts about the deal last week.

At that briefing, which was closed to journalists, Weber said that Takeda was mulling a takeover offer for all of Shire and that there was scope to increase debt, according to analysts.

According to two Reuters sources with direct knowledge of the matter, the Japanese drugs giant has now sounded out creditors, including its main bank Sumitomo Mitsui Banking Corp.

Reports in Japan have suggested that Takeda is looking for loans of several trillion yen – equivalent to tens of billions of dollars – in total from several banks.

Representatives for Takeda, Shire and Sumitomo Mitsui Banking Corp were not immediately available for comment.

Shire shares were up 2.1% to £36.65 in early afternoon trade, and they have now gained almost 25% since news of Takeda’s interest first broke.

View full SHP profile View Profile

Shire Plc Timeline

Related Articles

surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use